Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Klekotka

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Journal of the American Academy of Dermatology|October 22, 2011
Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanerceptJerry Bagel, Charles Lynde, Stephen Tyring, et al.
Frontiers in Immunology|November 1, 2024
Systematic literature review on early clinical evidence for immune-resolution therapies and potential benefits to patients and healthcare providersPaul Klekotka, Louis Lavoie, Beth Mitchell, et al.
The Journal of Dermatological Treatment|August 1, 2014
Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasisHema N Viswanathan, Dina Chau, Cassandra E Milmont, et al.
Journal of the American Academy of Dermatology|January 3, 2015
Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasisKim Papp, Alan Menter, Bruce Strober, et al.
The Journal of Investigative Dermatology|June 8, 2012
The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findingsDavid A Martin, Jennifer E Towne, Gregory Kricorian, et al.
Journal of the American Academy of Dermatology|October 15, 2014
Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatmentKim Papp, Craig Leonardi, Alan Menter, et al.
Infectious Diseases and Therapy|September 4, 2024
Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Trial for Mild-to-Moderate COVID-19Dipak R Patel, Lisa Macpherson, Martin Bohm, et al.
Chest|July 31, 2015
Biomarker Profiles in Asthma With High vs Low Airway Reversibility and Poor Disease ControlWilliam W Busse, Stephen T Holgate, Sally W Wenzel, et al.
Health and Quality of Life Outcomes|July 18, 2016
Development of the chronic obstructive pulmonary disease morning symptom diary (COPD-MSD)Gary Globe, Brooke Currie, Nancy Kline Leidy, et al.
Journal of Clinical Pharmacology|May 22, 2014
Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studiesChristopher J Endres, David H Salinger, Kathleen Köck, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Journal of the American Academy of Dermatology|October 22, 2011
Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanerceptJerry Bagel, Charles Lynde, Stephen Tyring, et al.
Frontiers in Immunology|November 1, 2024
Systematic literature review on early clinical evidence for immune-resolution therapies and potential benefits to patients and healthcare providersPaul Klekotka, Louis Lavoie, Beth Mitchell, et al.
The Journal of Dermatological Treatment|August 1, 2014
Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasisHema N Viswanathan, Dina Chau, Cassandra E Milmont, et al.
Journal of the American Academy of Dermatology|January 3, 2015
Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasisKim Papp, Alan Menter, Bruce Strober, et al.
The Journal of Investigative Dermatology|June 8, 2012
The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findingsDavid A Martin, Jennifer E Towne, Gregory Kricorian, et al.
Journal of the American Academy of Dermatology|October 15, 2014
Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatmentKim Papp, Craig Leonardi, Alan Menter, et al.
Infectious Diseases and Therapy|September 4, 2024
Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Trial for Mild-to-Moderate COVID-19Dipak R Patel, Lisa Macpherson, Martin Bohm, et al.
Chest|July 31, 2015
Biomarker Profiles in Asthma With High vs Low Airway Reversibility and Poor Disease ControlWilliam W Busse, Stephen T Holgate, Sally W Wenzel, et al.
Health and Quality of Life Outcomes|July 18, 2016
Development of the chronic obstructive pulmonary disease morning symptom diary (COPD-MSD)Gary Globe, Brooke Currie, Nancy Kline Leidy, et al.
Journal of Clinical Pharmacology|May 22, 2014
Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studiesChristopher J Endres, David H Salinger, Kathleen Köck, et al.
Pageof 5